C

Cencora

Distributes medicines and supports patient care

Batching Systems Automation Technician

Full-TimeUpdated on 10/20/2026
No salary listed
Junior, Mid
Bachelor's, Associate's
Texas, USA
RemoteFrequent travel to rural customer locations; approximately 25% ongoing and up to 50% during initial training.
Field ServiceEquipment Field Service

About the job

Requirements
  • An associate’s degree in Agricultural Engineering, Precision Agriculture, Electrical Engineering, Animal Science, Industrial Technology, or a related technical field, or completion of technical trade school or apprenticeship training in electrical systems, automation, or industrial technology.
  • One to three years of experience in agricultural operations, industrial automation and networking, PLC systems, or electrical systems.
  • Proficiency in troubleshooting hardware and software systems.
  • Professional verbal and written communication skills.
  • Working knowledge of 120V, 240V, and 480V AC systems, including single- and three-phase power; 12V and 24V DC control systems; relays, switches, contactors, circuit protection, and UPS devices; RS-232, RS-422, and RS-485 serial networks; Ethernet configurations in high-interference environments; and 900 MHz radio systems.
  • Ability to install, operate, and support system control software on Linux-based systems; support system updates, configuration changes, and software deployments; use command-line tools; work with SQL databases using query and management tools; support Java-based applications and related services; and analyze time-series system logs.
  • Ability to work independently in field environments, travel, work safely outdoors and around industrial machinery, lift equipment, and participate in a rotating on-call schedule.
  • Valid driver’s license and ability to pass background and drug screening.
  • Typically, an associate’s degree or equivalent from a two-year college or technical school, or six months to one year of related experience, or a combination of education and experience.
Responsibilities
  • Install, configure, and support PLC-based batching and control systems.
  • Integrate automation systems with scales, flow meters, pumps, augers, and other batching equipment.
  • Support integration between batching software and field equipment.
  • Diagnose and resolve automation and control system faults.
  • Install, operate, and support system control software on Linux-based systems; support updates, configuration changes, and software deployments; use command-line tools to monitor and troubleshoot system behavior; work with SQL databases; support Java-based applications and related services; and analyze time-series system logs to diagnose system behavior.
  • Build and repair communication cabling and connections; interpret electrical schematics and wiring diagrams; diagnose and troubleshoot electrical issues on-site and remotely.
  • Coordinate with millwrights, electricians, plumbers, and other tradespeople.
  • Train operators and other key personnel on system use and workflows; assist customers in diagnosing software, electrical, and automation issues; and provide real-time technical support during active operations.
  • Verify batching accuracy and system performance; monitor timing, sequencing, and communication; and prepare accurate, actionable reports of system observations.
  • Travel to rural customer locations for installation, troubleshooting, repair, and training, including up to 50% travel during the first three months and approximately 25% ongoing.
  • Participate in a rotating 24/7 on-call support schedule.
Desired Qualifications
  • A bachelor’s degree.
  • Bilingual Spanish skills.
  • Experience with livestock operations and high-volume feed batching.
  • Experience with industrial communications, including serial and radio systems.
  • Experience with Linux operating systems.
  • Experience with SQL databases.

About the company

Cencora buys and distributes medicines for pharmacies, hospitals and physician practices, while helping drug manufacturers bring treatments to patients. Its businesses combine wholesale supply networks with specialty distribution for complex therapies and services that support prescribing and patient access. Customers order medicines through its distribution systems, and its teams manage sourcing, storage and delivery alongside pharmacy operations and manufacturer support. It earns revenue from pharmaceutical sales and fees for logistics and healthcare services. The parent company was formed in 2001 through the merger that created AmerisourceBergen, adopted the Cencora name in 2023, and is headquartered in Conshohocken, Pennsylvania.

Company Size

10,001+

Company Stage

IPO

Headquarters

Conshohocken, Pennsylvania

Founded

2001

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Pharmacy contracts deepen customer ties: Cencora negotiates insurer agreements and handles administrative work through its managed-care networks.
  • Eligible US staff gain retirement support: Cencora counts student-loan payments toward its employer match, up to 4% of pay.
  • Drug demand expands sales: Cencora reported 5.1% quarterly revenue growth in August 2026, led by higher US volumes.

What critics are saying

  • Customer dependence concentrates risk: Walgreens and Boots supplied 25% of Cencora's fiscal 2025 revenue, reported in November 2025.
  • Legal liabilities tie up cash: Cencora's November 2025 filing recorded $4.3 billion in opioid settlements, payable over 13 years.
  • Warehouse work is physical: Cencora's day-shift associate listing requires repeated lifting up to 50 pounds and overtime availability.

What makes Cencora unique

  • Independent pharmacies get a shared brand: Cencora's Good Neighbor Pharmacy franchise supports their merchandising and store identity.
  • Specialty shipments use reusable packaging: Cencora's World Courier Cocoon containers combine passive temperature control with live location monitoring.
  • Medicines arrive ready for bedside checks: Cencora's American Health Packaging sells barcoded unit doses that support hospital scanning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Paid Parental Leave
  • Adoption Assistance
  • Infertility Coverage
  • Family Planning Benefits
  • Behavioral Health Solutions
  • Professional Development Budget
  • Training Programs

Company News

Yahoo Finance
Oct 16th, 2026
Cencora stock: $332.8B revenue, 14.4% EPS growth and 50.2% ROIC

Cencora, the pharmaceutical distributor formerly known as AmerisourceBergen, has risen 6% to $341.69 per share over the past six months. The S&P 500 gained 9.7% in the same period. The New York Stock Exchange-listed company (NYSE:COR) connects drug manufacturers with healthcare providers and offers logistics, data analytics, and consulting services. It rebranded in 2023. Its revenue reached $332.8 billion over the past 12 months, giving it scale and bargaining power with suppliers. That matters in a low-margin, volume-driven business. Earnings per share grew at a 14.4% compound annual rate over five years, outpacing 10.2% annualised revenue growth. Its five-year average return on invested capital was 50.2%. The shares trade at 17.4 times forward earnings.

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.

MarketScreener
Aug 5th, 2026
Cencora boosts credit facility to $7B, extends maturity to 2031

Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.